Status:
COMPLETED
A Single Dose Trial in Healthy Caucasians and Japanese Subjects Investigating the Pharmacokinetics of Somatropin
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Growth Hormone Disorder
Adult Growth Hormone Deficiency
Eligibility:
MALE
20-50 years
Phase:
PHASE1
Brief Summary
This trial was conducted in the United States of America (USA). The aim of this clinical trial was to investigate the pharmacokinetics of somatropin in healthy Japanese and Caucasian subjects, and to ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Signed informed consent before any trial related activities
- Japanese and Caucasian males respectively
- Healthy subjects based upon medical history, physical examination, vital signs, ECG, serum biochemistry and haematology and urinalysis
- Body Mass Index (BMI) between 17 and 30 m2/kg, inclusive
Exclusion
Key Trial Info
Start Date :
April 6 2000
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 8 2000
Estimated Enrollment :
86 Patients enrolled
Trial Details
Trial ID
NCT00931476
Start Date
April 6 2000
End Date
June 8 2000
Last Update
February 27 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Honolulu, Hawaii, United States, 96814-4224